ASH 2023 | Ibrutinib added to autoSCT conditioning and consolidation for patients with ABC-DLBCL

Charalambos Andreadis, MD, MSCE, UCSF Health, San Francisco, CA, discusses a randomized Phase III trial (NCT02443077) which aimed to evaluate the addition of ibrutinib to standard conditioning and consolidation therapy for patients with relapsed/refractory (R/R) activated-B-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL) who underwent autologous stem cell transplantation (autoSCT). This trial was launched in 2016 and experienced some challenges in the accrual process due to competition with novel therapies and difficulty effectively screening for this disease subtype. Unfortunately, this led to the early termination of the trial. However, Dr Andreadis highlights that the data collected suggest that ibrutinib with autoSCT was well-tolerated and may improve outcomes in this high-risk patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.